latest news releases from the newsroom
NeoNet's New Issue Oversubscribed
STOCKHOLM, Sweden, April 7, 2004 (PRIMEZONE) -- The subscription period for NeoNet AB's new issue of subordinated debentures with detachable warrants, with preferential rights for NeoNet's shareholders, ended on April 6. Submitted subscriptions so far, also including applications to subscribe through subsidiary preferential rights and applications to subscribe without preferential rights, show that the new issue has been significantly oversubscribed. NeoNet expects to be able to provide information regarding the final status of subscription during next week.
iBX Group, Inc.
Florida Healthsource Adds Age-Management Treatment Centers
DEERFIELD BEACH, Fla., April 7, 2004 (PRIMEZONE) -- Florida HealthSource, a network of physical therapy, occupational therapy and rehabilitation centers throughout the state and a division of iBX Group, Inc. (OTCBB:IBXG), today announced the launch of the Aevum HealthSource network, which will operate a physicians' network to provide patients with age-management and life-enhancement protocols and treatments.
Sampo PLC AGM Statement
STOCKHOLM, Sweden, April 7, 2004 (PRIMEZONE) -- Sampo plc's Annual General Meeting today decided, in accordance with the proposal of the Board of Directors, to pay a dividend of EUR 1.50 per share for 2003. The record date for dividend payment is 14 April 2004 and the dividend will be paid out on 21 April 2004. The Annual General Meeting approved the financial accounts and discharged the accountable parties from liability.
Alfa Laval has decided to file a lawsuit against the former owner of bioKinetics Inc.
STOCKHOLM, Sweden, April 7, 2004 (PRIMEZONE) -- Alfa Laval made public in December 2003 that the company had decided to initiate new negotiations with the former owner of bioKinetics Inc. This decision was based on the fact that Alfa Laval suspected irregularities in the accounting of certain customer projects in the acquired US company. The negotiations have not led to any settlement. Alfa Laval has therefore decided to file a lawsuit against the former owner of bioKinetics Inc and certain individuals.
Dr. Jean-Marie Dupuy Accepts Position on ProtoKinetix Board of Directors
VANCOUVER, British Columbia, April 7, 2004 (PRIMEZONE) -- Dr. John Todd, president of ProtoKinetix, Inc. (OTCBB:PKTX), is pleased to announce that Dr. Jean-Marie Dupuy has accepted a position on the ProtoKinetix Board of Directors. Dr. Dupuy will be responsible for the Company's medical research efforts and is currently in Paris working with the Georges Pompidou Hospital on the clinical evaluation trials for the BioCurex (OTCBB:BOCX) RECAF molecule. As Medical Research Director, Jean-Marie will consult with major European institutions concerning potential product collaboration. The following abbreviated resume will serve to outline the qualifications of this internationally acclaimed medical scientist.